Results 171 to 180 of about 4,188,222 (350)

CD47 promotes mitogen‐activated protein kinase and epithelial‐to‐mesenchymal transition molecular programs to drive prometastatic phenotypes in non‐small cell lung cancer

Molecular Oncology, EarlyView.
Beyond its role in immune evasion, this study identified that CD47 drives tumor‐intrinsic signaling in non‐small cell lung cancer (NSCLC). Transcriptomic profiling and functional studies revealed that CD47 regulates cell adhesion, migration, and metastasis through an ERK–EMT signaling axis.
Asa P.Y. Lau, Lilian G. Zhai, Ryunosuke Hoshi, Zackary Rousseau, Abraam Zakhary, Yin Fang Wu, Rola M. Saleeb, Heyu Ni, Kelsie L. Thu   +8 more
wiley   +1 more source

Editorial: Growth regulation in horticultural plants: new insights in the omics era

Frontiers in Plant Science, 2023
Chenxia Cheng, Nan Ma, Yi Zheng, Yi Zheng, Lin Xi   +4 more
doaj   +1 more source

Quality by Design-Based Formulation Development of an Oral Semaglutide Tablet. [PDF]

Pharmaceutics
Yoon JH, Kim DH, Kim JE.
europepmc   +1 more source

KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer

Molecular Oncology, EarlyView.
Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.
Jennie N Jeyapalan, Veronika M Metzler, Simone de Brot, Corinne L Woodcock, Anna E Harris, Jennifer Lothion‐Roy, Emeli M Nilsson, Atara Ntekim, Michael S Toss, Jenny L Persson, Francesca Khani, Brian D Robinson, Lorraine J Gudas, Emad Rakha, David M Heery, Catrin S Rutland, Nigel P Mongan   +16 more
wiley   +1 more source

PLGA-Based In Situ-Forming Implants, a Quality by Design Perspective. [PDF]

Pharmaceutics
Campos-Morales N, Cervantes-Pérez LG, Sánchez-Mendoza A, Sánchez-Aguilar M, Escobar-Chávez JJ, Martínez-Acevedo L, Galindo-Pérez MJ, Miranda-Calderon JE.   +7 more
europepmc   +1 more source

Heterozygous loss‐of‐function alleles associate the conserved 3′‐5′ exoribonuclease EXOSC10 with hypersensitivity to the anticancer drug 5‐fluorouracil

Molecular Oncology, EarlyView.
EXOSC10, an essential nuclear RNA exosome‐associated 3′‐5′ exoribonuclease, is inhibited by the anticancer drug 5‐fluorouracil (5‐FU), and EXOSC10 depletion increases 5‐FU sensitivity. The colon‐cancer variant EXOSC10S402T, located in a proteolysis motif, is stable and nuclear but nonfunctional in vivo.
Radhika Sain, Yann Le Page, Frédéric Percevault, Emmanuelle Becker, Luc Negroni, Almudena Fernandez, Marta Cantero, Diego Muñoz‐Santos, Lluís Montoliu, Cyrille Garnier, Michael Primig   +10 more
wiley   +1 more source

Integrating theory and practice: the core components guide for rigorous quality improvement design. [PDF]

Front Health Serv
Howard P, Arrieta J, Leruth C, Bones K, Steinfield R, Figueroa J, Olaya SP, Barker P.   +7 more
europepmc   +1 more source

Cost/ Benefit Model Development of Quality Management with Profit Design

, 2013
In this research, the cost/ benefit model will be developed to integrate quality management with profit design on relevant processes. The profit should be properly allocated on quality conformance, quality improvement, and quality attraction by the ...
Lee, Hsu-hua
core  

Cell‐cycle‐specific lesion evolution rather than inhibition of double‐strand‐break repair underpins cisplatin radiosensitization

Molecular Oncology, EarlyView.
We analyze cisplatin–DNA adducts (CDAs) and double‐strand breaks (DSBs) in a cell‐cycle‐dependent manner. We find that CDAs form similarly across all cell cycle phases. DSBs arise only in S‐phase. CDAs might not directly impair DSB repair, but S‐phase DSB lesions evolve in the presence of CDAs and disrupt repair in G2, also causing radiosensitization ...
Ye Qiu, Xixi Lin, Emil Mladenov, Veronika Mladenova, Jürgen Thomale, Ali Sak, Yao Wang, Yunxuan Deng, Eleni Gkika, Martin Stuschke, George Iliakis   +10 more
wiley   +1 more source

Blockchain-enabled quality by design system for clinical trials. [PDF]

Front Med (Lausanne)
Vatankhah Barenji R, Hariry RE.
europepmc   +1 more source